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RIASSUNTO 
Le porfirie sono un gruppo di malattie metaboliche ereditabili legate alla biosintesi 
dell’eme. Ogni tipo di porfiria è caratterizzata da un peculiare accumulo di precursori 
dell’eme generato da una specifica alterazione della via biosintetica. Queste malattie 
rare sono caratterizzate da un’estensiva eterogeneità di mutazioni a carico della 
regione codificante dei geni direttamente o indirettamente coinvolti nel pathway. 
In questo studio, abbiamo valutato tre nuove varianti identificate nelle regioni 
regolatorie del gene PPOX utilizzando linee cellulari di epatocarcinoma (Hep3B) e 
di leucemia eritroide (K562). Abbiamo dimostrato una minore espressione del gene 
PPOX attraverso saggi di luciferasi e analisi del RNA legata alla variante c.1-
883G>C, localizzata sul promotore del gene, e abbiamo suggerito un ruolo post-
trascrizionale per le varianti c.1-413G>T e c.1-176 G>A site nel 5’UTR della variante 
2 del mRNA del gene PPOX. Esperimenti di transfezione del plasmide mutante 
reporter -413T, indicano che questa variante inibisce la traduzione del mRNA della 
luciferasi della firefly associata al vettore. In effetti, la ridotta attività della luciferasi 
della firefly non è correlata con una proporzionale riduzione dell’espressione del 
mRNA del reporter. I valori normali dei livelli del mRNA del gene PPOX nel paziente 
portatore della sostituzione c.1-413G>T, validati tramite Digital PCR, supportano 
questa evidenza. I dati per la variante c.1-176 G>A, mostrano un suo possibile ruolo 
a livello di regolazione dello splicing. L’analisi qualitativa del RNA conferma che 
questa mutazione è coinvolta nella soppressione del normale splicing tra l’esone 1 
e l’esone 2 dovuto a una delezione di 4 bp nell’esone 1. La relazione tra queste 
alterazioni post-trascrizionali e la porfiria variegata devono essere ulteriormente 
investigate. Questi risultati suggeriscono di includere nel processo diagnostico 
anche le regioni regolatorie dei geni, per cui ulteriori studi sono richiesti per chiarire 
il loro ruolo nella malattia. 
Per creare un modello per le porfirie epatiche, abbiamo creato delle cellule simili agli 
epatociti a partire dalle cellule pluripotenti indotte generate dalle cellule del sangue 
di due pazienti affetti da porfiria acuta intermittente, un tipo di porfiria epatica.  
Abbiamo ipotizzato che questo potesse servire come un modello in vitro per studiare 
i diversi pathway legati alla porfiria acuta intermittente. 
I dati suggeriscono un profilo generale comparabile della via biosintetica dell’eme tra 
cellule simili agli epatociti derivanti dalle cellule pluripotenti indotte e gli epatociti 
primari. Nonostante la permanenza di alcuni caratteri di immaturità, legati ai limiti 
della riproduzione in vitro degli epatociti, che potrebbero direttamente o 
indirettamente alterare il network metabolico legato alle porfirie epatiche, al 
momento le cellule simili agli epatociti derivanti da cellule pluripotenti indotte sono 
tra i migliori modelli per studiare le malattie epatiche. 
Le cellule simili agli epatociti derivanti dalle linee cellulari dei pazienti hanno indicato 
una maggiore espressione basale del gene ALAS1 e dei suoi regolatori PPARA e 
PGC1A accompagnata dall’induzione di geni coinvolti nella risposta al danno 
ossidativo. Inoltre, l’induzione di geni correlati alla chetogenesi e al metabolismo dei 
lipidi mette in luce un differente profilo metabolico delle linee cellulari dei pazienti 
affetti da porfiria acuta intermittente.  
La simulazione in vitro di un attacco acuto mediante trattamento con ALA, uno dei 
principali composti accumulati durante l’attacco acuto, ha mostrato una regolazione 
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negativa sull’espressione dell’ALAS1 e una massiva induzione dell’HMOX1 nella 
linea cellulare differenziata controllo. Dall’altra parte, la risposta al Fenobarnital nelle 
cellule di controllo suggerisce il legame della sintesi del colesterolo e della 
gluconeogenesi con la via biosintetica dell’eme. Il metabolismo del farmaco infatti, 
induce il pathway biosintetico dell’eme attraverso ALAS1, e questo gene risulta 
costantemente overespresso nelle linee cellulari dei pazienti.   
In conclusione, questo studio focalizza l’attenzione sull’importanza delle regioni 
regolatorie nei processi diagnostici della porfiria e fornisce un modello in vitro 
alternativo per studiare le alterazioni metaboliche legate alle porfirie. Ulteriori 
esperimenti sono necessari per una migliore comprensione degli effetti diretti delle 
alterazioni nelle regioni regolatorie dei geni legati alle porfirie, e sono richiesti per 
analizzare il coinvolgimento delle differenti vie metaboliche concorrenti 
all’espressione della malattia. 
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ABSTRACT 
Porphyrias are a group of inherited metabolic disorders of heme biosynthesis. Each 
porphyria derives from an alteration in the heme biosynthetic pathway resulting in a 
specific accumulation of heme precursors. These rare diseases are characterized 
by an extended heterogeneity of mutations affecting the coding region of the genes 
directly or indirectly involved in the pathway. In this study, we assessed three new 
variants identified in the regulatory regions of the PPOX gene using human 
hepatocarcinoma (Hep3B) and erythroleukemia (K562) cell lines. We demonstrated 
a lower expression of the PPOX gene through luciferase assays and RNA analysis 
for the c.1-883G>C promoter mutant and we suggested a post-transcriptional role 
for the c.1-413G>T and c.1-176G>A variants in the 5′ UTR of PPOX mRNA variant 
2. Transfection experiments of mutant -413T reporter plasmid indicate that this 
variant inhibits translation of the downstream firefly luciferase mRNA. In fact, the 
reduced firefly luciferase activity did not correlate with the proportional reduction in 
firefly luciferase mRNA expression. Normal values of PPOX mRNA level validated 
with Digital PCR in the patient carrying the c.1-413G>T substitution support this 
evidence. Data for the c.1-176G>A variant show a possible role in the spicing 
regulation for it. The qualitative RNA analysis confirms that this variant is involved in 
the alteration of the normal splicing between exon 1 and exon 2 of PPOX due to a 4 
bp deletions in exon 1. The relation between these post-transcriptional alterations 
and the variegate porphyria remains to be investigated. These results suggest that 
the regulatory regions have to be considered in the diagnostic process but more 
studies are required to clarify their role in the disease. 
To model hepatic porphyrias, we derived hepatocyte-like cells from hiPSC generated 
from blood of two patients affected by acute intermittent porphyria, a hepatic 
porphyria. We hypothesized that this can serve as an in vitro model to study different 
pathways linked with acute intermittent porphyria.   
The data suggest a general comparable profile of the heme biosynthec pathway 
between hiPSC-HLC and primary hepatocytes. Although some immature features, 
probably linked with the in vitro condition, could directly or indirectly affect the 
metabolism network links with hepatic porphyrias, now hiPSC-HLCs are one of the 
most useful model available for hepatic diseases.  
The patient derived hepatocyte-like cells showed a basal overexpression of ALAS1 
and its regulator PPARA and PGC1A with induction of oxidative damage response 
genes. Moreover, the induction of ketogenetic and lipid metabolic genes highlighted 
a different metabolic profile in the acute intermittent porphyria patient lines.  
The in vitro simulation of acute attack mediated by ALA administration, one of the 
principal compound accumulated during the attack, showed a negative feedback 
regulation on ALAS1 with massive induction of HMOX1 in the control cell line.  
On the other hand, phenobarbital response in control line suggested the link between 
cholesterol synthesis and gluconeogenesis with the heme biosynthetic pathway. The 
drug metabolism in fact, induces the heme biosynthetic pathway through ALAS1, 
and this gene results constantly overexpressed in the derived patient cell lines. 
In conclusion, this study focus the attention on the importance of the regulatory 
regions in the diagnostic process of porphyrias and supply an alternative in vitro 
model to study the metabolic alterations linked with porphyrias. Further experiments 
are required to better understand the direct effect of alteration in the regulatory 
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regions of porphyria genes and are necessary to analyse the involvement of different 
pathways in the onset of the disease. 
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INTRODUCTION 
1.1 Porphyrias  
Porphyrias are a group of metabolic disorders due to the accumulation of 
porphyrin precursors and porphyrins results from the impairment in the heme 
biosynthetic pathway. Each is caused by a partial or almost total deficiency 
in one of the enzyme involved in the pathway combining to bring about 
chemical intermediates peculiar for each form of seven known types of 
porphyria. The cytotoxic porphyrinogens, with chemical and photoreactive 
properties, are responsible of the clinical features of the disease such as 
neurovisceral symptoms and cutaneous lesions. Despite the co-presence in 
some form of porphyria of neurologic manifestation and photosensitivity, 
porphyrias can be clinically classified in acute and cutaneous[1]. 
Acute porphyrias - acute intermittent porphyria (AIP), variegate porphyria 
(VP) and hereditary coproporphyria (HCP) - present acute attacks due to the 
accumulation of 5-aminolevulinic acid (ALA) and/or porphobilinogen (PBG) 
that are markedly detectable in the urine during the attack. In spite of 
autosomal dominant inheritance of the disease, acute porphyrias are often 
misdiagnosed for the non-specific symptoms such as abdominal pain, 
vomiting, nausea, constipation, hypertension, and tachycardia. Moreover, 
the low penetrance of the disease hides latent patients that could remain 
asymptomatic throughout life. The neurological symptoms derive from the 
direct and indirect effects of the overproduced porphyrin precursors ALA and 
PBG. It has been suggested an alteration of the metabolic state of the cells 
due to heme deficiency affecting hemeproteins like tryptophan dioxygenase, 
leads to an increased serotonergic activity. In addition, a malfunction of 
another hemeproteins, the cytochromes P450, may alter neuronal 
transmission and the detoxifying capacity of the cell. It has been proposed 
also a direct neurotoxic effect of ALA acting on the GABAergic system as 
partial GABA agonist inducing the central nervous system dysfunction. 
Patients will often also have peripheral neuropathy but the mechanism of the 
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damage is not well understood[2]. The identification of carriers of the 
diseases is important to avoid the exposure to porphyrinogenic drugs that, 
with other events including hormonal changing related to the menstrual cycle, 
diet, alcohol and stress, could trigger the acute attacks. Porphyric attacks 
occur mainly after the puberty and affect predominantly women[3].  
On the other hand, the skin lesions present in cutaneous porphyria result 
from the accumulation of reactive porphyrins where the presence of the 
tetrapyrrolic ring in a photoreactive form produces damage that promotes 
loss of membrane integrity and oxidation of cellular components. 
The feature of the porphyrin structure is its photoreactive to radiation energy 
in the visible range. By absorbing about 400 nm, porphyrins are excited to a 
singlet state and they relay the energy absorbed to biomolecules dangerous 
after oxidation, promoting cellular damage and inflammation. The 
immunohistochemical analysis of the patient skin suggests the blood vessel 
of the dermis as principal site of photo injury. The clinical symptoms of the 
different cutaneous form are linked with the physiochemical properties of the 
accumulated porphyrins that can affect cytosolic target in case of enzymatic 
blocks of uroporphyrinogen III synthase (UROS), uroporphyrinogen 
decarboxylase (UROD), coproporphyrinogen oxidase (CPOX) and 
protoporphyrinogen oxidase (PPOX) or lipid-rich cellular structure due to 
ferrochelatase (FECH) deficiency[4]. Lesions are restricted to sun-exposed 
areas and hyperpigmentation, hypertrichosis and skin fragility are features of 
the cutaneous poprhyrias. The excretion profile of urinary and faecal 
porphyrins with also the concentrations in erythrocytes of free protoporphyrin 
and the plasma porphyrin fluorescence assay are useful parameters in the 
specific diagnosis of porphyria (table 1).  
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Considering the site of production and accumulation of porphyrins, porphyria 
can be also classified as either erythroid or hepatic porphyria. The 
erythropoietic porphyrias are characterized by overproduction and 
accumulation of pathway intermediates in bone marrow, whereas in hepatic 
porphyrias, the overproduction and accumulation of ALA, PBG and 
porphyrins occur in the liver. In light of this classification there are four acute 
hepatic porphyrias (acute intermittent porphyria, hereditary coproporphyria, 
variegate porphyria and ALA-dehydratase porphyria), a single hepatic 
cutaneous porphyria (porphyria cutanea tarda) and three erythropoietic 
Table 1: Porphyrias: clinical and biochemical features. Porphyrias can be classified 
according to the clinical symptoms in neurovisceral and cutaneous. Each porphyria 
present a peculiar biochemical pattern, important in the diagnosis of the disease.  
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cutaneous porphyria (X-linked protoporphyria, congenital erythropoietic 
porphyria and erythropoietic protoporphyria)[5].  
 
1.1.1 Acute intermittent porphyria  
Acute intermittent porphyria (AIP) is the most frequent hepatic porphyria and 
results from a deficiency of the porphobilinogen deaminase (PBGD) enzyme 
encoded by the hydroximetylbilane synthase (HMBS) gene.  It is an 
autosomal dominant disease with low penetrance manifestation. The acute 
attack generated by different endogenous and exogenous factors are 
biochemically marked by the urinary overexcretion of ALA and PBG and a 
plasmatic peak at 618-620 nm. The neurovisceral symptoms are usually 
intermittent and reversible and affecting principally the women after 
puberty[6].  
The HMBS gene is located at chromosome 11q24.1–24.2[7] and is 
composed by 15 exons. Alternative splicing transcripts are generate from the 
same gene for the erythroid specific and ubiquitous isozymes. The 
housekeeping promoter is located upstream the exon 1 while the erythroid 
promoter, recognized by erythroid specific transcription factors, is in the 
intron 1. The erythroid enzyme differs in the amino-terminal sequence part 
17 additional  amino acid residues contained in the ubiquitous enzyme[8].  
The use of mouse model has been used to study the mitochondrial energetic 
failure and glucose metabolism linked with acute intermittent porphyria[9]. At 
now, only one study was performed to study the biochemical and pathologic 
alteration in the liver of a transplanted AIP patient[10]. 
1.1.2 Variegate porphyria and PPOX gene 
Variegate porphyria is a low penetrance autosomal dominant hepatic 
porphyria due to enzymatic defect of protoporphyrinogen oxidase. The acute 
attacks are associated with urinary excretions of ALA, PBG uro- and 
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coproporphyrins combined with a plasmatic peak at 624-627 nm. The 
neurovisceral symptoms may occur with photosensitivity[6].  
The PPOX is transcribed by the gene localized in the 1q22.23 region[11]. A 
single promoter controls the housekeeping and erythroid transcription. 
Tissue specific variants producing the same functional protein have been 
isolated. The shorter variant 1 has been isolated in different tissues such as 
liver, heart, pancreas, brain, placenta, lung, kidney and skeletal muscle[12]. 
The variant 2 was predominant in leukocytes.  
The promoter region contains CCAAT box and Sp1 binding site for the basal 
transcription activity localized in the upstream part of the promoter[13], 
whereas the erythroid transcription is supported by GATA-1 binding sites in 
the 5’UTR region[14] but the tissue specific and induced transcription remain 
unknown. The gene is composed by 13 exons where the exon 1 and a 
section of exon 2 are part of the 5’UTR of the gene.  The starting of translation 
(ATG) is located in the exon 2[13]. 
 
1.2 Heme biosynthetic pathway 
This is one of the most conserved pathways between all the species leads 
the formation of a tetrapyrrolic structure associated to different metals 
constitutive of the “pigments of life”. The heme in particular, is composed by 
a Fe2+ ion conjugated with the protoporphyrin IX produced by the sequential 
action of eight enzymes located between the mitochondria and cytosol of all 
the cells[15]. The synthesis of the heme starts in the mitochondria from the 
condensation of succinyl Co A and glycine by the enzyme ALA synthase 
(ALAS) to form 5-aminolevulinic acid (ALA) (fig. 1). 
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The human ALAS is coded by two different genes, one for the housekeeping 
form, ALAS1 on chromosome 3, and one for the erythroid form, ALAS2 on 
chromosome X. The condensation of two molecules of ALA in one molecule 
of porphobilinogen (PBG) is made by ALA dehydratase (ALAD) and takes 
place in the cytosol. Subsequent to the link of four molecules of PBG by 
porphobilinogen deaminase, the hydroxymethylbilane is cyclized in 
uroporphyrinogen III by uroporphyrinogen III synthase (UROS). In the 
absence of UROS, the hydroxymetilbilane can spontaneously cyclizes to 
form first the uroporphyrinogen I and after decarboxylation, the isomeric 
coproporphyrinogen I. The uroporphyrinogen decarboxylase (UROD) 
catalyzes the sequential decarboxylation of four carboxylic group of the 
acetic-acid side to form coproporphyrinogen III. After the transport into 
mitochondria, the coproporphyrinogen oxidase (CPOX) catalyzed the 
formation of vinyl groups by the removal of two of the four propionate groups. 
Then, the protoporphyrinogen IX is oxidated in protoporphyrin IX by 
Fig 1 Heme biosynthetic pathway. From succynil CoA and glycine through the action 
of the eight enzyme of the pathway between mitochondria and cytosol there is the 
formation of the tetrapyrrolic ring conjugated with Fe2+, heme. 
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protoporphyrinogen oxidase (PPOX).  The terminal step of the pathway is 
catalysed by the ferrochelatase (FECH) responsible of the insertion of the 
iron into the tetrapyrrolic ring to form the heme[16].  
The heme is the main component of the hemeproteins involved principally in 
the transport and storage of oxygen, the sterols, lipids and neurotransmitters 
metabolism, oxidative stress reaction, control and generation of the energetic 
metabolism of the cells[17]. Although heme is produced in all the cells for the 
essential respiratory and energetic reactions, it is mainly synthetized in the 
bone marrow to for haemoglobin during erythroid differentiation (80% of the 
synthesis) and in the liver (15% of the synthesis) as constituent of 
cytochromes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2 Differential control of heme biosynthetic pathway in bone marrow and 
liver. During hematopoiesis, ALAS2 is active for the production of heme involved in 
the haemoglobin formation. It is induced by erythropoietin and iron. In the liver ALAS1 
is recruited for supplying of the heme for different hemeprotein, cytochromes involved 
in drug metabolisation and respiratory chain. ALAS1 is negatively regulated by heme. 
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The two tissues differ principally on the control on the first rate limiting 
enzyme of the pathway, ALAS 2 for the erythroid cells and ALAS 1 for the 
liver and all the other cells and reflect also the differential request of heme 
between the organs (fig 2). 
ALAS 2 has to support the constant production of haemoglobin and it is 
induced by erythropoietin in response to hypoxia signal. Thereafter, induction 
of transcriptional factors as GATA1, CACC box and NFE2 activates the 
expression of ALAS2 that is post-transcriptionally controlled by the 
availability of iron in the cell. In iron deficiency in fact, the IRE-binding 
proteins bind the IRE sequence located in the 5’untranslated region of 
ALAS2 and prevent the accumulation of toxic protoporphyrins[18]. The 
impairment of activity of ALAS2 causes X-linked sideroblastic anemia for iron 
overload due to insufficient synthesis of protoporphyrins, or X-linked 
erythropoietic porphyria as result of ALAS2 activity increase[19].  
In the other cells and especially in the liver, ALAS1 has to support the rapid 
metabolic changes requiring hemeproteins. This rate-limiting step is 
regulated through negative feedback by the free heme pool. The inhibitory 
action of heme on ALAS1 occurs at different levels. Together with a 
repressive action on transcription and degradation of mRNA, heme prevents 
the mitochondrial translocation of ALAS1. On the other hands, the 
upregulation of ALAS1 is mediated indirectly by HMOX1 through the 
catabolism of heme. Additionally, transcriptional factor as PGC1and 
PPARcontribute to ALAS1 induction and participated to the precipitation of 
acute attacks linked with drugs, hormonal and glucose metabolism[20]. 
Considering the central role as pathogenetic triggering actor in acute 
porphyria patients, hepatic ALAS1 is the target of a phase I clinical trial with 
a RNAi conjugated with GalNAc, a ligand for a liver-specific receptor, to 
reduce the activity of the enzyme and the accumulation of the toxic 
porphyrins[21]. 
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1.3 Heme catabolism 
To prevent the toxic accumulation of compound derived by production of 
porphyrin precursors and porphyrins, the cells are able to handle heme 
leftover from the breakdown of heme proteins by the heme catabolism.  
Heme oxigenase 1 (HMOX1) is a protein ubiquitously expressed but is 
principally induced in liver and spleen, where the main catabolism of 
haemoglobin takes place.  
The enzyme cleaves one of the methane bridges of the porphyrin ring in 
concert with NADPH cytochrome reductase with generation of carbon 
monoxide. Then, the linear tetrapyrrol biliverdin, is oxidized to bilirubin with 
release of available iron for the cell. 
HMOX1 is induced by different stimuli as heavy metals, oxidative stress 
organic chemicals and heme by its self. Stimuli that increase HMOX1 may 
thereby trigger clinical symptoms in some forms of porphyria by overload of 
the deficient enzyme due to the lack of heme free pool on the pathway 
dependent on HMOX1 activity[4]. 
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1.4 Human induced pluripotent stem cells (hiPSCs) 
The human induced pluripotent stem cells (hiPSCs) are reprogrammed 
somatic cells that after the introduction of four crucial genes, octamer-binding 
transcription factor 4 (OCT4), sex determining region Y (SRY)-box 2 (SOX2), 
krüppel-like factor 4 (KLF4) and cellular homolog of v-myc avian 
myelocytomatosis viral related oncogene (c-Myc), have all the pluripotency 
characteristics as the self-renewal and the capacity differentiation toward all 
the three somatic germ layers: ectoderm, mesoderm and endoderm[22]. 
The possibility to generate expansible and tissue specific differentiated cells 
from somatic cells as fibroblast or blood cells, opened the opportunity to 
multiple applications such as disease modelling, drugs screening and 
autologous transplantation.  The capacity of these cells to differentiate in any 
tissue, offers the opportunity to create in vitro a disease modelling 
maintaining the genetic background of the patients and reproducing the 
phenotype of the original donor. Their potential will permit in the future the 
use of these cells for individual drug screening or gene therapy application. 
Different methods have been proposed for the delivery of the reprogramming 
factors including viral vectors integration in the DNA of host cells or by 
reproducing of the vector restricted in the cytoplasm. Other methods as small 
molecules and episomal vector are recently used for the transgene-free 
human reprogramming[23] .  
 
 
 
 
 
 
 
 
 Milena Bellin et al Nature Reviews Molecular Cell Biology  2012 
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1.5 Stem cells derived hepatocytes 
The capacity of pluripotent stem cells to generate all cell type of the human 
body makes them the ideal cell type to establish disease modelling on tissues 
that are hard to study for the limited source of primary tissues. The liver is 
metabolic hub of the body interacting with different tissues as gastrointestinal 
tract, skeletal muscle and adipose tissue by crosstalk with the neuronal and 
hormonal systems. The liver is a complex organ composed by different cell 
types with specific functions. The hepatocytes are the major cell type and 
participate to the principal liver functions. They control the body energy 
metabolism by glucose and ammonia homeostasis, fatty acid biosynthesis 
and degradation, cholesterol and glycogen synthesis and they express 
detoxification capacity mediated by CYPs drug metabolisation activity. 
Several transcription factors and coactivators control liver energy 
metabolism and make the important metabolic switch in the fed or fasted 
states to store or synthetize glucose under the tightly control of insulin and 
other metabolic hormones[24]. 
The protocol of hepatic differentiation has the goal to produce efficiently and 
in a reproducible manner cells with phenotypic and metabolic feature of 
primary hepatocytes. 
Functionally, the primary hepatocytes express mature markers as albumin, 
transthyretin (TTR) and urea synthesis. Moreover, they presents high 
expression of drug metabolizing enzymes, cytochromes P450s, and 
transporter proteins as NTCP, important for hepatothropic viral infection. 
Expression profile comparison between fresh human hepatocytes and stem 
cells derived hepatocytes showed a fetal hepatic phenotype for the 
Fig 3 From Nature Reviews Molecular Cell biology Milena Bellini et al 2012 Human 
iPS cell derivation, differentiation and application. Adult somatic can be 
reprogrammed into induced pluripotent stem (iPS) cells and differentiate in vitro for 
further applications as disease modelling, drug screening and discovery and toxicity 
tests.  
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hepatocyte-like cells derived from stem cells[25]. Many studies suggest an 
improvement of the in vitro culture conditions to create mature hepatocytes.  
The primary hepatocytes remain the gold standard cell type for application 
as drug metabolisation studies[26]. However the limited supply resource of 
donors and the quick dedifferentiation of primary hepatocytes in the in vitro 
culture conditions[26], limit their application on modelling disease supporting 
the use of stem cells derived hepatocytes.  
To differentiate hiPSCs toward hepatocytes, the initial endodermal 
commitment is mediate by Activin A and Wnt3A. The hepatoblast 
differentiation is driven by bone morphogenetic protein 4 (BMP4) and 
fibroblast growth factors 1 (FGF1) and 4 (FGF4) though hepatic endodermal 
specification. The final maturation step is promoted by hepatic growth factor 
(HGF). 
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AIM 
In the first part of this PhD project, we aimed to evaluate the functional role 
of nucleotide variants identified in variegate porphyria patients without other 
mutations in the coding region of the PPOX gene. 
To this end, we formulated the following objectives: 
 Expression assessment of the PPOX gene in the patients 
 Generation of reporter plasmid vector containing the mutated region 
of interest 
 Luciferase assay 
 RNA analysis 
In the second part of the PhD project, we aimed to generate human induced 
pluripotent stem cells to model hepatic porphyria. 
For this part of the project the objectives were: 
 Generate human induced pluripotent stem cells from blood samples 
of the patients with high quality standard value 
 Differentiate the hiPSCs into hepatocyte, and value the capacity of 
the AIP patients lines to follow the differentiation program 
 Metabolic characterization of the differentiate hepatocyte derived 
from AIP patients 
 Expression analysis of pathways related with AIP phenotype 
 Reproduction in vitro of acute attack by porphyrinogenic compounds 
and drugs treatment 
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MATERIALS AND METHODS 
3.1 Patients 
Five unrelated patients with symptomatic and clinical indication of variegate 
porphyria and two unrelated patients with molecular diagnosis of acute 
intermittent porphyria were recruited. Peripheral blood samples were 
collected in accordance with ethical principles and after signature of the 
informed consent approved by ethics committees of the Fondazione IRCCS 
Cà Granda Ospedale Maggiore Policlinico di Milan and KU Leuven. 
3.2 Plasmid construction and luciferase assays 
The plasmid construction and luciferase assay is described in the paper[27]. 
Briefly, the region with the promoter and 5’UTR of the PPOX gene was 
isolated by polymerase chain reaction and TA cloned into pGL4.10 plasmid. 
To generate promoter plasmids with the mutation of interest, the wild type 
promoter-pGL4.10 construct was directly mutagenised by QuikChange Site-
Direct Mutagenesis Kit (Stratagene, La Jolla, California, USA). To perform 
the luciferase assay after transient transfection using Fugene Transfection 
Reagent (Promega Corp. Madison USA) of the constructs in presence of 
Renilla Luciferase-TK vector as efficiency control, the luciferase activity was 
determined by Dual-Luciferase Report Assay System with GloMax Discovery 
system (Promega Corp. Madison USA) 48h after transfection. The relative 
luciferase activity was calculated after normalization of the Firefly on Renilla 
activity and the data were  expressed as a ratio of activity of the mutated 
promoter/reporter construct and that obtained for wild-type promoter/reporter 
construct, under the same conditions (FI; fold induction). 
  
3.3 Peripheral Blood Mononuclear Cells extraction 
The samples were diluted with PBS (1:1) and extracted by Ficoll separation 
using Ficoll Paque Premium reagent (GE Healthcare). After centrifuge 
separation for 5 min at 300xg, the peripheral blood mononuclear layer was 
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extracted and washed with PBS 3 times. The cells were stored in liquid 
nitrogen.  
3.4 Cell cultures 
The human hepatocellular carcinoma cell line (Hep3B) and human 
erythroleukemia cell line (K562) were cultured as described in [27] 
The peripheral blood mononuclear cells were cultured in SFEMII media with 
L-glutamine (2mM), SCF, FLT3, IL-3 and IL-6.  
The reprogrammed cells were initially cultured in peripheral blood 
mononuclear cells media. After 5 days, the cells were cultured in ReproTeSR 
Reprogramming medium in presence of Mouse Embryonic Fibroblast. After 
20 days they were cultured in E8 flex Medium (Invitrogen) on human qualified 
Matrigel (BD Bioscience). 
The hiPSC were differentiated towards hepatocytes following a previously 
described protocol with modifications under patent’s protection[28]. 
The cells were incubate at 37°C with 5% of CO2. 
The Sigma cell line used as control are the iPSC epithelial-1 from Sigma-
Alderich. To limit epigenetic memory differences between the iPSC derived 
from different tissues, the differentiation process was induced after several 
cell division passages.   
3.5 Sendai reprogramming 
The transduction of 2,5*105 cells was performed with the CytoTune iPS 2.0 
Sendai Reprogramming Kit following the manufacturer’s procedure 
(Invitrogen).  
3.6 RNA extraction and quantitative reverse transcription PCR 
The total RNA was extracted by Maxwell 16 LEV simplyRNA Blood Kit 
(Promega Corporation) following the manufacturer’s procedures. The total 
RNA was reverse transcribed using high-capacity cDNA archive kit. The 
PPOX expression was analysed on ABI PRISM 7500 real time PCR system 
(Thermofisher) using TaqMan gene expression assays in combination with 
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TaqMan Universal Mater mix. Custom assays for firefly and Renilla luciferase 
were designed. Primer list and Taq Man assay codes in [27] 
The RNA from derived-hepatocytes and primary cell lines was isolated by 
the GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich) following 
manufacturer’s procedures. Genomic DNA contamination was degraded by 
On-Column DNase 1 Digestion kit (Sigma-Aldrich). The Superscript III First-
Strand synthesis system (Invitrogen) was used for the cDNA synthesis. The 
quantitative real-time PCR was performed in a Vii7 Real Time PCR 
instrument (Thermofisher) with the Platinum Sybr green qPCR supermix-
UDG kit (Invitrogen). The data were normalized with the 2-CT method[29] 
using the Ribosomal Protein L19 (RPL19) as housekeeping. 
3.7 Digital PCR and qualitative RNA analysis 
The qualitative RNA analysis and confirmation of PPOX relative gene 
expression was described in [27]. Briefly, the 25 ng of cDNA was loaded to 
QuantStudio 3D Digital PCR 20K Chip with 1X of QuantStudio 3D Digital 
PCR Master mix and 1X of Taqman assay. The housekeeping and target 
gene expression was determined by independent assays. The ratio of the 
target on endogenous gene express as copies/l were compared to value of 
the subject control. For the qualitative RNA analysis, the region of interest 
was amplified from cDNA sample and submitted to direct sequencing. 
3.8 Intracellular flow cytometry 
The intracellular AAT flow cytometry staining was performed on a single cell 
suspension made by liberase treatment (Roche) and fixed with 4% of PFA. 
The permeabilisation was mediated by a 0,1% of saponin solution blocked 
for 45 min with 10% of goat serum (Dako). The cells were stained with 62,5 
ng/200 l/106 cells anti-AAT antibody (Dako) or rabbit IgG isotype control (BD 
Pharmigen) for 1h at room temperature. The secondary Alexa Fluor 647 
antibody (1:1500)(Invitrogen) was incubate with cells for 30 min at RT. Cells 
were analysed by flow cytometry analysis using a FACS-Canto (BD). 
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3.9 Immunofluorescence 
Cells were fixed with 4% of PFA and the permeabilisation with 0,2% Triton 
X-100 was blocked with 5% donkey serum (Jackson Laboratory). The cells 
were stained overnight at 4°C with the primary antibodies and isotype 
controls. The cells were later incubate with the appropriate secondary 
antibodies together with Hoechst (Sigma-Aldrich) for 60 minutes at room 
temperature. The images were generated by AxiomagerZ.1 fluorescence 
microscope. 
3.10 Albumin ELISA 
The albumin ELISA was performing according to the manufacturer’s 
procedure (Bethyl) on the media collected at D20 of the differentiation 
protocol. The supernatant was incubate with a primary albumin antibody for 
1 h. The HRP- detection antibody was added for 1h and afterward, the TMB-
peroxidase solution was added for 15 min. The reaction was stopped by a 
0,18M H2SO4 solution. The OD was measured on a microplate reader at a 
wavelength of 450 nm. The amount of albumin was calculated using a 
generated standard curve. 
3.11 CYP assay 
The CYP assay was performed using the fluorometric probe 7-benzyloxy-4-
trifluoromethylcoumarin (BFC) as described by [30] specific for the CYP3A4 
metabolism. 
Metabolisation was measured after 1h of incubation times. 
3.12 Statistical analysis 
The data were analysed by GraphPad Prism software. The statistical 
analysis was performed by unpaired t test after normal distribution 
verification through R Shapiro test. 
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RESULTS 
4.1 Characterization of the functional role of new variants involved in 
variegate porphyria 
4.1.1 Identification of new variants in symptomatic patients with 
variegate porphyria 
Five patients with clinical and biochemical features of variegate porphyria 
(VP) carried three different variants in the promoter and 5’UTR region of the 
PPOX gene (NC_000001.11): c.1-883G>C, c.1-413G>T, c.1-176G>A. Three 
of them presented the c.1-176G>A variant. These variants are not common 
polymorphisms in the Single Nucleotide Polymorphysm (dbSNP) and Exome 
Aggregation Consortium (ExAC) databases. No other alteration or mutations 
were detected in the coding region of the gene.  
4.1.2 PPOX gene expression in the patients 
To determine the possible down-regulation of PPOX in the patients with the 
new identified variants, we performed quantitative real-time PCR (qRT-PCR) 
and digital PCR on the RNA extracted by the peripheral blood of the patients 
and healthy controls. The results showed a lower expression of the gene 
compared to two different housekeeping only in the patient with the c.1-
883G>C variant (Fig 5).  
 
 
 
 
 
 
 
Fig 5 Relative expression of PPOX gene. (A) qRT-PCR of the PPOX mRNA detected 
in the blood of the patients. The relative expression was compared to healthy controls 
after normalization against two different housekeeping genes. The results are reported 
as the mean ± SD of three independent experiments. ** indicates p values<0,005. (B) 
Digital PCR expression assy. The relative expression in the patients results as ratio of 
the copies/l of the target gene on the endogenous compared to the healthy control with 
a confidence level of 95% and  precision below 10%. GUSB was used as housekeeping 
gene. 
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4.1.3 Luciferase assay to characterize the functional role of the 
variants 
 To investigate the role of the variants, the region of interest was cloned 
upstream the reporter gene Luc2 into the pGGL4.10 basic vector (fig 6).  
 
 
The wild type and mutated constructs were transfected in Hep3B and K562 
cell lines and the activity of the luciferase was normalised on the Renilla 
luciferase co-transfected as internal control. The results indicated a 
significant reduction of the luciferase activity in both cell lines for the -883C 
and -416T constructs, in contrast with a normal activity for the -176A 
construct with a more evident effect on Hep3B.  
Fig. 6 Plasmid construction. A region of 1114bp including the promoter and 5’UTR region 
of the PPOX gene was cloned in the pGL4.10 vector upstream the reporter Luc2.The c.1-
883G>C is located in the promoter, while the c.1-416G>T  and c.1-176G>A in the 5’UTR 
indicated in upper bold case. The arrow indicates the alternative splice site of the variant 1. 
The circle indicates the alternative splice generated by the c.1-176G>A variant. 
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Considering the localisation of the variants in the promoter and 5’UTR of the 
PPOX gene, we quantified the mRNA level of luciferase in the transfected 
cells to clarified the level of regulation on the PPOX content due to these 
variants. The relative mRNA quantification  showed a lower expression of 
luciferase for the -883C construct, proportional with the lower activity of the 
enzyme. In contrast with a reduced activity of luciferase, the mRNA content 
of the -413T construct was similar to the wild type construct, as well as for 
the -176A construct in both cell lines. The data for the -413T construct 
suggested a translational involvement of the variant more than a 
transcriptional role (fig 7). 
 
 
 
 
 
 
 
4.1.4 Qualitative mRNA analysis to test the c.1-176G>A variant 
To determine the role of the c.1-176G>A variant, located in the last 
nucleotide of the 5’ untranslated exon 1 of the PPOX gene, we performed 
the qualitative reverse transcription PCR (RT-PCR) selecting the region 
between exon 1 and exon 3. No difference were highlighted in the 
amplification data of the patients compared to the controls on agarose gel 
verification. The direct sequence of the mRNA, by contrast, indicated a 
Fig 7 Luciferase assays. (A) Relative firefly luciferase activity in Hep3B and K562 cell 
lines. The data results from the ratio between Luciferase and Renilla activity compared 
to the wild type construct (Ctrl). pGL4.10  indicates the empty vector. *=pvalue <0,05; 
**=pvalue<0,005. (B) Relative Luc2 expression in the transfected cell lines. The relative 
expression of Luc2 was normalized against Renilla mRNA and was compared to the 
cells transfected with the wild type construct (Ctrl). pGL4.10  indicates the empty vector. 
*=pvalue <0,05; **=pvalue<0,005. The results are reported as the mean ± SD of three 
independent experiments. 
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deletion of 4bp in all patient with the c.1-176G>A variant indicating a splicing 
modulation role for it by activation of a cryptic splicing site (Fig 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mRNA originated by this variant did not showed stability alteration as 
shown by previous relative and qualitative assay of PPOX gene in the 
patients. The direct effect on the protein level remain unknown. 
 
 
 
 
 
 
 
 
 
Fig 8 Electropherograms of RNA direct sequencing. The panel A indicates the wild 
type sequence from a healthy donor. The panel B shows a frameshift due to a 4bp 
deletion in all the patients carrying the c.-176G>A variant. The red star indicates the 
beginning of the frameshift.  
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4.2 HiPSC derived hepatocytes like cells to model hepatic porphyrias 
4.2.1 Generation of hiPSC from AIP patient lines 
To model hepatic porphyrias we generated two human induced pluripotent 
stem cell (hiPSC) lines from the peripheral blood of two unrelated 
symptomatic patients with acute intermittent porphyria (AIP). 
To demonstrate the reprogramming of the somatic cells to iPSCs, we tested 
the absence in the different clones of the Sendai viral vector and the 
expression of pluripotency markers as SOX2,OCT4 and NANOG through 
quantitative RT-PCR.  The pluripotency was also confirmed with 
immunofluorescence staining of undifferentiated iPSCs for the pluripotency 
markers SOX2, OCT4 and NANOG and embryoid body formation assay, 
followed by ScoreCard® analysis. The single-nucleotide polymorphisms 
(SNPs) profile indicated no difference between the blood original samples 
and the generated clones. Moreover, we selected clones without significant 
genome-wide aberrations on aCGH-array (Fig 9). 
 
 
 
 
 
 
 
 
 
 
Fig 9 Characterization of hiPSCs from acute intermittent porphyria patients. (A) 
Expression of cMyc and Sendai virus in the individual clones. (B) Embryoid body formation 
assay demonstrating differentiation to the three germ layers and loss of pluripotency (C) 
Expression of pluripotency marker SOX2, OCT4 and NANOG compare to GAPDH. (D) 
hiPSC were stained for NANOG, SOX2 and OCT4. (E) Comparative genomic hybridization 
(CGH) assay. Clones present Derivative Log Ratio (DLR) <0.20.  
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The presence of the mutation of patient 1 (AIP1) and patient 2 (AIP3) in the 
generated hiPSC lines was validated with direct sequencing and compared 
to the Sigma cell line used as control sample (Fig.10) 
 
 
 
 
 
 
 
 
 
 
 
4.2.2 Differentiation of hiPSCs in HLCs 
The hiPSCs were differentiated toward hepatocytes-like cells (HLCs) using 
a differentiation protocol of 20 days, adapted from the protocol described in 
[28]. To validate the HLCs as model for porphyria, we first analysed the 
expression of genes involved in the heme biosynthetic pathway in the healthy 
donor Sigma iPSC derived HLCs and primary human hepatocytes (PHHs) 
from three different healthy donors. 
Although the expression analysis demonstrated a comparable profile for the 
genes of the pathway, there was a significant reduction for ALAS1 and CPOX 
that might be linked with the immature phenotype of HLCs (Fig.11).  
 
 
 
 
A B 
Fig 10. Direct sequencing of hiPSCs from AIP1 and AIP3. (A) The sequencing of 
Sigma cells (upper panel) showed presence of the wild-type G base in position c.799 of 
HMBS gene (NM_00190.3) while in the AIP1 iPSC line G was replaced by C. (B) 
Sequencing of Sigma cells in position c.913-2 identified an A while the A was replaced 
by a G in the AIP3 iPSC line.  
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The HLCs from the healthy donor Sigma, AIP1 and AIP3 iPSC lines showed 
the typical cuboidal shape of differentiated HLCs (fig 12) and the flow 
cytometry analysis on HLCs stained with an antibody against alpha-1-
antytrypsin demonstrated that 88-98% stained positive (fig 13). 
 
 
 
 
 
 
 
 
Fig 11. The heme biosynthetic pathway in PHH and Sigma derived HLCs. Expression 
of the heme biosynthetic pathway was similar between the PHH and Sigma derived HLCs 
with the exception of ALAS1 and CPOX. The results are reported as mean of the absolute 
expression for each gene ± SD relative to RPL19 expression of three independent 
experiments. PHH represents primary human hepatocytes plated for 24h derived from 
three unrelated healthy donors. Statistical analysis performed with unpaired t-test after 
normal distribution verified with R Shapiro.test. *=pvalue<0.05; **=pvalue<0,005 indicate 
significant difference between the Sigma HLCs and PHH.  
Fig.12 Cuboidal shape of the hiPSC-derived HLCs. Bright-field microscopy images of 
HLCs at D20. Similar images where produced by 3 independent different experiments. 
** 
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We next performed qRT-PCR to assess expression of a series of marker 
genes involved in hepatic differentiation and we compared the HLCs-derived 
lines from the two patients with the HLCs-derived from the Sigma control line. 
Some transcripts, such as ALB and HNF6, were lower express in the HLCs 
derived from the two patient lines, while HNF4 and AAT were comparable to 
the healthy control line or more highly expressed in AIP3 derived cells 
(Fig14).  
 
 
 
 
 
 
 
 
Fig 13 Flow cytometry analysis. FACS demonstrated that approximatively 90% of cells 
were positive for AAT for Sigma (A), AIP1 (B) and AIP3 (C) HLCs. This analysis is 
representative of two independent HLCs differentiation experiments for each cell line.  
 26 
 
 
However, the absolute mRNA transcript numbers for ALB and HNF6 were in 
the general range observed for multiple hepatocyte differentiations in the 
Verfaillie lab (4000-250/1000 copies of RPL19 for ALB and 250-15/1000 
copies of RPL19 for HNF6) for each differentiation experiment.   
To further exclude that hepatocyte-like differentiation of AIP lines was 
defective, we valued the expression levels of genes involved in glycolysis, 
that are generally more expressed in undifferentiated and dedifferentiation 
cells. HLCs derived cells from the AIP lines expressed lower transcript levels 
for LDHA, HKII and PFKB3, related to glycolysis. Moreover, G6PC and 
PEPCK, two gluconeogenic genes, were higher expressed in AIP3 HLCs (fig 
15). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.14 Transcript levels of genes involved in hepatic differentiation. AIP HLCs lines 
expressed lower transcript levels of ALB and HNF6 and comparable transcript levels for 
HNF4 and AAT compared to HLCs derived from Sigma control line. The results are 
reported as mean ± SD of three independent experiments. RPL19 was used as 
housekeeping gene. Unpaired t-test was performed after verification of normal 
distribution with R Shapiro.test. *=pvalue<0,05; **=pvalue<0,005; ***=pvalue<0,001 
indicate significant difference between the AIP HLCs and control AIP. 
. 
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Moreover, we tested albumin secretion and CYP3A4 activity. Although ALB 
transcript levels were lower in AIP HLCs, there was no significant difference 
in ALB secretion between patient and Sigma control HLCs and CYP3A4 
activity was similar as well (fig 16). 
 
 
 
 
 
 
 
 
4.2.3 Metabolic pathways in HLCs derived from AIP patients 
As acute intermittent porphyria is a disease affecting PBGD, the third enzyme 
in the heme biosynthetic pathway, we tested the genes involved in this 
pathway to determine if alterations exist linked with PBGD impairment.  
ALAS1 transcript levels were increased in AIP1 and AIP3 HLCs compared 
to Sigma HLCs. In addition, transcripts for PPARA were elevated in AIP3 
HLCs, more so than AIP1 HLCs, compared to Sigma HLCs; while expression 
of PGC1A, FECH, HMOX1 and TRANSFERRIN transcripts was elevated 
only in AIP3 HLCs. In AIP1 was also detected an induction of HMBS 
transcripts (Fig 17). 
Fig 15 Glycolysis and gluconeogenesis related genes expression level of HLC 
derived cells from the tree cell lines. The AIP1 and AIP3 HLCs expressed lower levels 
LDHA and HKII and no difference in PKM2 compared to the Sigma control HLCs. G6PC 
and PEPCK were strongly induced in AIP3 derived cells. Results are reported as mean ±SD 
of three independent experiments. RPL19 was used as housekeeping gene. Unpaired t-test 
performed after verification of normal distribution with R Shapiro.test. *=pvalue<0,05; 
**=pvalue<0,005; ***=pvalue<0,001 indicate significant difference between the AIP HLCs 
and control AIP. 
 
Fig. 16 Functional analysis of AIP1 and AIP3 HLCs derived lines. No difference in 
albumin secretion and CYP3A4 activity was seen in patient HLC compare to control  Sigma 
HLCs. Results are representative of two independent experiments. 
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To confirm haploinsufficiency of PBGD in spite of the normal transcript levels 
for HMBS, we tested the activity of the enzyme. The residual activity of the 
enzyme was lower than 40% in the two patient HLCs derived cells, in line 
with the diagnosis of acute intermittent porphyria (fig 18). 
 
  
 
 
 
 
 
 
 
Fig. 17 Heme biosynthetic pathway in HLCs derived cell patient lines. The genes 
involved in the heme biosynthetic pathway were induced in HLCs derived cells from the 
patients compared to control Sigma HLCs. Results are reported as mean ±SD of three 
independent experiments. RPL19 was used as housekeeping gene. Unpaired t-test was 
performed after verification of normal distribution with R Shapiro.test. *=pvalue<0,05; 
**=pvalue<0,005; ***=pvalue <0,001 indicate significant difference between the AIP HLCs 
and control AIP. 
 
 
Fig. 18 PBGD activity. The PBGD activity was measured as picomoles of uroporphyrin 
production normalized on the proteins concentration. N=1. 
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Interestingly, the AIP HLCs expressed higher levels of HMGSC, a gene 
involved in ketone body formation and cholesterol synthesis. To further 
investigate these pathways, we analysed the expression of the thiolases, 
upstream in the HMGCS and the transcript level of HMGCR, the gene coding 
for the rate limiting enzyme of the cholesterol biosynthetic pathway.   
We found an increased expression of HMGS2 and HMGCR in both AIP 
HLCs, suggesting an induction of the cholesterol synthetic pathway and fatty 
acid oxidation. This was substantiated by the observation that also 
transcripts for ACAT1 and ACAT2 in AIP3 HLCs  were increased, as well as 
ACAA2, the thiolase specific for ketone body formation (fig 19). 
 
 
 
 
 
 
 
 
 
To determine if the AIP-HLCs were subject to greater oxidative stress, as we 
demonstrated elevated levels for ALAS1 in both patients derived HLCs, as 
well as transcripts for FECH and HMOX1 in AIP3 HLCs, we tested by qRT-
PCR transcript levels for glutathione synthase (GSS), glutathione S-
transferase (GST), uncoupling protein 2 (UCP2) and catalase (CAT). 
Fig.19 Ketone bodies and cholesterol synthesis related genes. Both HLCs patient 
lines presented the induction of the HMGS2, involved in both ketone body formation and 
cholesterol synthesis, and the most specific gene for cholesterol synthesis HMGCR. The 
thiolases for these pathways were also induced in AIP3 HLCs. Unpaired t-test was 
performed after verification of normal distribution with R Shapiro.test. *=pvalue<0,05; 
**=pvalue<0,005; ***=pvalue<0,001 indicate significant difference between the AIP HLCs 
and control AIP. 
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Elevated levels of the three genes were found in AIP1 and AIP3 HLCs, 
suggesting increased oxidative stress possibly related to unstable oxygen-
contain molecules (Fig.20) 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.4 Effect of 5-delta aminolevulinic acid (ALA) in hiPSCs-derived 
hepatocytes 
To mimic an acute attack and as a result of induction of ALAS1 in the two 
HLCs AIP derived lines, we added 300 M of 5-aminolevulinic acid (ALA) to 
the to the HLC culture medium for the last 24 hours. 
In the HLCs derived from the Sigma control line, we observed an induction 
of FECH and HMOX-1, indicating that the ALA provided was used in the 
heme biosynthetic pathway (fig 21). 
 
 
 
Fig 20 Induction of oxidative stress response in HLCs derived lines from AIP1 and 
AIP3. Both AIP HLCs expressed higher levels of oxidative damage response genes 
compare to the HLCs derived from Sigma control line. Unpaired t-test was performed 
after verification of normal distribution with R Shapiro.test. *=pvalue<0,05; 
**=pvalue<0,005; ***=pvalue<0,001 indicate significant difference between the AIP HLCs 
and control AIP. 
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The decreased levels of ALAS1 may suggest presence of a residual amount 
of heme acting in the known negative feedback control of ALAS1. 
The level of ALAS1 was also consistent with a downregulation of PGC1A, 
which might be caused by increased glucose import due to the increased 
expression of GLUT1 (fig 22). 
 
 
 
 
 
 
 
 
Fig. 21 Induction of heme biosynthesis mediated ALA. In presence of ALA, the heme 
biosynthetic pathway was induced, as shown by increased levels of FECH. In addition, and 
possibly by increased production of heme, we also observed  an induction of HMOX1. 
Unpaired t-test was performed after verification of normal distribution with R shapiro.test. 
*=pvalue<0,05; difference between Sigma HLCs without and with ALA. 
 
Fig. 22 Effect of ALA on ALAS1. ALAS1 was downregulated in the presence of ALA as 
well as PGC1A, while GLUT1 was induced. Unpaired t-test was performed after verification 
of normal distribution with R Shapiro.test. *=pvalue<0,05; ***=pvalue<0,001 difference 
between Sigma HLCs without and with ALA. 
 
 32 
Moreover, no induction of genes involved in the oxidative stress response 
pathway was seen, indicating that the oxidative stress observed in the AIP 
HLCs may not be directly dependent on the presence of ALA.  
The gene expression pattern AIP HLCs demonstrated similarities with Sigma 
HLCs treated with 300 M of ALA. The induction of heme pathway genes as 
FECH in AIP1 and BLVR, the gene involved in heme catabolism, in both 
treated AIP HLCs were observed. Also in both AIP HLCs, we observed a 
decrease in ALAS1 and PPARA (fig 23) combined with increased levels of 
GLUT1 when ALA was added the last 24h (fig 24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 23 Effect of ALA on heme metabolism related genes. In the presence of ALA 
there were induction of FECH and BLVR. ALAS1 was lower in both AIP-HLCs combined 
with a down regulation of PPARA *=pvalue<0,05; **=pvalue<0,005 ***=pvalue<0,001 
indicate significant differences in comparison to the relative AIP-HLCs lines without 
ALA. 
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Finally, in the presence of ALA, we found an induction of the thiolase ACAT2 
(fig 25) in HLCs derived from AIP1 cell lines, and no other variations in the 
already high level of genes involved in cholesterol and ketone body formation 
was seen as in normal condition without ALA for HLCs-AIPs (fig 19).  
 
 
 
 
 
 
 
 
 
Fig. 25 ACAT2 overexpression in presence of ALA in the HLC-derived AIP lines. In AIP1 
HLCs, an induction of ACAT2 expression was found following addition of ALA. *=pvalue<0,05 
indicates significant differences in comparison to AIP1 HLCs without ALA. 
 
Fig 24 Effect of ALA on GLUT1. In the presence of ALA there was overexpression of 
glucose transporter GLUT1 in both AIP-HLCs. *=pvalue<0,05; **=pvalue<0,005  
indicate significant differences in comparison to the relative AIP-HLCs lines without 
ALA. 
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4.2.5 Effect of phenobarbital in HLCs derived cells 
One of the inducers of porphyric attacks in acute intermittent porphyria is 
phenobarbital. Therefore, we added 200 mg/ml phenobarbital the last 24h of 
the differentiation to mimic the acute attack, and assessed the effects at the 
transcription of genes linked with the metabolic changes of in AIP HLCs. 
Phenobarbital induced gene expression within the heme biosynthetic 
pathway, including ALAS1, ALAD, HMBS and genes linked with the iron 
transport transferrin (TF) and mitoferrin in Sigma-derived HLCs. The 
unchanged expression levels of HMOX1, but increased expression of other 
members of the pathway, suggests that as higher levels of heme are needed, 
catabolism through HMOX1 may not be occurring. Induction of ALAS1 was 
also associated with overexpression of PPARA and PGC1A (fig 26). 
 
 
 
 
 
 
 
 
 
 
 
PB caused an oxidative stress response in the Sigma HLCs as shown by the 
increased expression of GST, UCP2, ATP5A1, CAT and GSS (fig 27).  
Fig. 26 Expression profile of the heme biosyntethic pathway after phenobarbital 
(PB) treatment in control Sigma HLCs. PB treatment induced the heme biosynthetic 
pathway with overexpression of key genes as ALAS1, ALAD and HMBS, in presence of 
induction of transferrin (TF) and mitoferrin. Induction of PPARA and PGC1A was also 
found following PB treatment. *=pvalue<0,05; **=pvalue<0,005; ***=pvalue<0,001 
indicate significant differences in comparison to control Sigma HLCs not treated with PB 
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More interestingly, after PB treatment the metabolic genes of control Sigma 
HLCs was changed. We observed an induction of the thiolase ACAA2 
involved in ketone body formation, as well as ACAT1, ACAT2 and HMGCR 
important in cholesterol synthesis. This suggests that these pathways are 
activated in response of drug metabolism. Moreover, the increased 
expression of GLUT2 and PEPCK suggest that there may be an increased 
need for glucose in this metabolic context requiring in enhanced glucose 
transport and gluconeogenesis (fig 28). 
 
 
 
 
 
 
 
 
Fig 27 The phenobarbital induce oxidative stress in control Sigma HLCs. After 
treatment with PB there was induction of genes related with oxidative stress response. 
*=pvalue<0,05 and **=pvalue<0,005 indicate significant differences in comparison to 
control Sigma HLCs not treated with PB 
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As also seen for the Sigma HLCs, PB induced expression of the GLUT2 
glucose transporter and PEPCK in HLCs derived from AIP1 and AIP3 
patients iPSCs (fig 29), whereas no further induction of ALAS1 and its 
regulator genes were observed after phenobarbital treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 28 Induction of ketogenesis, cholesterol synthesis and gluconeogenesis in 
presence of phenobarbital. Sigma HLCs were treated with 200mg/mL PB. We detected 
an induction of genes linked with ketogenesis, such as ACAA2, and cholesterol synthesis, 
such as ACAT1, ACAT2 and HMGCR. Moreover, the glucose transport GLUT2 and 
gluconeogenic gene PEPCK were induced *=pvalue<0,05 and **=pvalue<0,005  indicate 
significant difference in comparison to HLCs Sigma control line 
 
Fig 29 Induction of GLUT2 and PEPCK. The glucose transport GLUT2 and 
gluconeogenesis PEPCK gene expressions were induced in both AIP-HLCs lines 
*=pvalue<0,05 and **=pvalue<0,005  indicate significant difference in comparison to relative 
AIP-HLCs lines without phenobarbital treatment. 
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Moreover, in AIP3-HLCs, PB also induced overexpression of ketogenic and 
cholesterol synthesis related genes in presence of induction of PXR and one 
of its target CYP2C9, one of the cytochromes involved in phenobarbital 
metabolism(fig 30).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 30 Metabolic changes in HLCs derived from AIP 3 iPSCs. Treatment with PB 
induced expression of genes involved in ketogenesis and cholesterol synthesis as the 
thiolase ACAT2 and ACAA2. PB also induces the expression of PXR and its target 
CYP2C9 involved in drug metabolism.*=pvalue<0,05 indicates significant difference in 
comparison to AIP 3 HLCs without treatment. N=3 
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DISCUSSION 
Porphyrias are a group of rare disease characterized by a variegate 
heterogeneity of mutations affecting the genes directly or indirectly involved 
in the heme biosynthetic pathway[5]. The majority of the mutations described 
are localised in the coding region of the genes that are included in the routine 
molecular diagnosis. On the other hands,  only few variants in the regulatory 
regions of the porphyric genes  have been reported in association with 
porphyrias [31][32] despite the high rate of mutation probability due for the 
less selective pressure on these regions[33]. The effects of variants in the 
regulatory regions are not predictable as for the coding variants, and required 
experimental confirmations.  
In this study, we proposed a putative role for variants in the regulatory region 
of PPOX gene identified in five symptomatic patients of variegate porphyria. 
The data for the c.1-883G>C located in the promoter of PPOX proposed a 
transcriptional role for this variant. The low expression measured in the 
patient, correlated with an impairment of the luciferase activity generated by 
the construct -883C. Moreover, the difference showed between the two 
different cell line transiently transfected with the construct, supports the 
different promoter activity in liver and erythroid cells of the PPOX gene 
previously reported[14]. Even if bioinformatics analysis[34] did not 
highlighted the loss of transcriptional binding site generated by the presence 
of the variant, the ChIP-seq database[35] indicate a high-density binding 
signal for different transcriptional factors. The c.1-883G>C might be involved 
in the stability of a complex essential for the transcription of the PPOX gene. 
The results for the c.1-413G>C suggest a post-transcriptional role for this 
variant. In spite of the normal expression of the PPOX in the patient, the 
transfected construct -413C generated a low activity luciferase signal. This 
reduction was not concord with the mRNA quantification of the exogenous 
luciferase vector transfected that was comparable to the wild type construct. 
The c.1-413G>C variant is located on the proximity of the transcriptional 
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starting site of PPOX, in a region recognized by the pre-initiation complex for 
the translation of the mRNA[36]. The presence of this variant could modify 
the binding ability of the complex but further experiments allowing the protein 
quantification on cells carrying this variant could clarify its effective role.  
In conclusion for the first part of the project, we also suggested a splicing 
modulation action for the c.1-176G>C substitution. 
This variant is located in the last nucleotide of the 5’UTR of the variant 2 of 
the PPOX gene, the most abundant variant isolated in human leucocytes[13]. 
The sequencing of the isolated mRNA of the patients showed a deletion of 
4bp due to the alternative splicing generated by the presence of the 
substitution. However, no difference in the mRNA expression of PPOX in the 
patients compared to normal controls, confirm a proper maturation of the 4bp 
deleted mRNA. The localization of the variant and the generated deletion 
could affect the post-transcriptional regulation of the gene by altering the 
interaction with cell specific trans-acting protein[37]. The predicted structure 
[35]of the PPOX 5’UTR indicate a stable stem loop structure, that could be 
targeted by tissue or environmental regulatory proteins. CAGE race 
experiments in association with minigene transfection assay could confirm 
the role of the variant in the protein generation. 
The second part of my PhD project was focused on the generation of human 
induced pluripotent stem cells derived hepatocyte like cells (HLCs) to study 
acute intermittent porphyria. 
Human induced pluripotent stem cells (hiPSC) have been proposed as a 
powerful technology for disease modelling for genetic diseases [22]. The 
generation of pluripotent stem cells directly from somatic cells of the patients 
allows the production of tissue-specific derived cells useful for 
pathophysiology studies in vitro using a versatile platform that maintains the 
genetic background of the patients [38]. Human hepatocyte-like cells derived 
from hiPSCs were previously used for liver disease in vitro modelling [39], 
infectious disease studies [40] and drug metabolisation screening[41]. 
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The use of Sendai viral vector-based reprograming constitutes an easy and 
integration free approach to generate hiPSC, as used in this thesis, from 
blood samples of two symptomatic acute intermittent porphyria (AIP) patients 
with recurrent acute attacks. 
The hiPSC were differentiated into hepatocytes using a modified 
differentiation culture condition protocol developed by Ruben Boon 
(Engineering of the nutrient microenvironment is indispensable for 
hepatic maturation of stem cell derived progeny and hepatoma cell 
lines Under review in Nature Biotechnology) that improves the metabolic 
maturation of in vitro HLCs, although they maintain some fetal marker 
expression.  
In this thesis, I demonstrated that HLCs showed a comparable expression 
gene profile with human primary hepatocytes, except for ALAS1, the gene 
encoding for the first rate-limiting enzyme of the pathway that was 
approximatively 2.5 times lower expressed. This is consistent with the 
observation by R. Boon, that the metabolic profile of HLCs, despite 
optimization of the culture conditions remains immature if performed without 
induction of hepatocyte and metabolic transcription factors. Nevertheless, as 
harvesting primary liver cells from patients is nearly impossible, and in view 
of the fact that culture of primary hepatocytes causes a very fast loss of 
mature hepatocyte functions, in vitro HLCs remain a good platform to perform 
pathophysiology studies applied to hepatic porphyrias. 
The only published study performed on hepatocytes from acute intermittent 
porphyria patients, found a notable overexpression of ALAS1 and HMOX1, 
without heme depletion [10]. Our results were in line with these data. In HLCs 
from both AIP patients, ALAS1 was increased consistently in association with 
an increase in PPARA and PGC1A transcripts. PPARA and PGC1A are 
known to be involved in ALAS1 induction [42][43] and are also linked to 
gluconeogenesis, glycolysis and fatty acid oxidation [44]. Analyzing the gene 
expression profile of genes involved in glucose metabolism, we noted some 
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differences compared to the Sigma control HLCs. The AIP HLCs expressed 
less glycolysis transcripts, and in AIP3 HLCs cells expressed higher levels 
of PEPCK, a gluconeogenesis related gene. Furthermore, in both patient 
derived HLCs there was an increase in expression of genes involved in 
cholesterol synthesis and fatty acid oxidation, suggesting a difference in 
energy homeostasis maintenance also in physiological conditions. These 
data were supported by previous observations of hypercholesterolemia in 
AIP patients and altered glucose metabolism. In contrast with data from a 
mouse model [45], our data suggest that also in basal conditions, and not 
only after fasting, glucose metabolism in AIP HLCs might be supported by 
gluconeogenesis and ketogenesis. Therefore, it may be interesting to assess 
ketobodies accumulation in porphyria patients, in which symptoms might also 
reflect ketoacidosis due to a crosstalk between the heme biosynthetic 
pathway and ketogenesis. This hypothesis will obviously require further 
studies. 
The increased expression of genes involved in the oxidative damage 
response in AIP-HLCs was in line with data observed by Ferrer et al in the 
circulating patient’s cells [46].  
To reproduce in vitro an acute attack, we used different strategies. We added 
300 M of 5-delta aminolevulinic acid (ALA), described as the concentration 
produced in hepatocytes during an acute attack [47]. In the ALA condition, 
the induction of FECH and HMOX1 expression in the control normal HLCs 
was indicative of increased heme biosynthesis. This was also suggested by 
the lower expression levels of ALAS1. This decrease might be mediated by 
the negative feedback control of heme on ALAS1, the rate-limiting step of the 
pathway. Interestingly, we found a concurrent induction of the glucose 
transporter GLUT1, which may be indicative of an increased basal glucose 
requirement upon heme overproduction. The absence of induction of other 
genes related to oxidative damage in normal control HLCs suggested that 
other metabolites in porphyria patients must be involved in this process. In 
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AIP HLCs, the increased need for glucose linked with heme biosynthesis 
induction in presence of ALA, was also suggested by the increase in 
gluconeogenesis and ketogenesis gene expression, with, in addition, a 
constant high level of the transcripts of genes involved in cholesterol 
synthesis.  
We also treated AIP and control HLCs with phenobarbital (PB), one of the 
porphyrinogenic drugs causing acute attack in acute intermittent porphyria 
patients. In response to PB, changes seen in control HLCs appeared to 
reproduce some of the phenotypic alterations seen in the AIP HLCs under 
non-stressed conditions, including effects on gene expression within the 
oxidative stress pathway, and induction of ketogenic and gluconeogenic 
genes, followed also by increased levels of transcripts of genes involved in 
cholesterol synthesis. 
Although induction of cholesterol synthetic genes has been described as 
consequence of phenobarbital-induced stimulation, the exact mechanism 
and the reason for this reaction remain unknown. Our observation that 
ALAS1 is induced in control HLCs in response to PB and the already base-
line increased expression of this gene in the AIP HLCs, suggests the 
hypothesis that the heme pathway may be involved in the induction of 
cholesterol synthesis, which could explain the hypercholesterolemia reported 
in some cases of acute intermittent porphyria [48].  
The continuous induction of the heme biosynthetic pathway in HLCs AIP line 
and the similar metabolic changes observed in the HLCs control line 
suggested an uninterrupted request of heme in patient lines that was induced 
in the HLCs control line to support the increased cytochromes synthesis and 
may be insufficient in AIP lines in basal conditions. We can now, not 
determine if the impairment of the pathway by a mutation of the HMBS gene 
leads to a heme deficiency. The overexpression of ALAS1 in the HLCs 
patient lines also in basal conditions may be due to a block of the negative 
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feedback mediated by heme, support this hypothesis. The quantification of 
heme produced will be required to further elucidate this finding. 
Homedan et al [9] demonstrated an energetic deficiency in a mouse model 
of acute intermittent porphyria due to mitochondrial energetic failure. They 
hypothesised this observation to be a consequence of a cataplerosis of TCA 
cycle caused by withdrawal of succinyl-CoA by ALAS induction. The 
oxidative stress observed in AIP HLCs and in control HLCs after PB induction 
of ALAS1 supports this hypothesis, not only in an acute attack context but 
even in basal conditions.  
The increased expression of glucose transporters, gluconeogenic and 
ketogenic genes, reinforce the notion of the important role played of the 
nutritional status on clinical expression of AIP. Collantes et al [45] described 
the role of alterations in glucose metabolism in AIP mice: during fasting in 
the AIP mouse model induced  gluconeogenesis and ketogenesis instead of 
glycogenolysis during nutritional deprivation. In addition, it was assumed that 
mitochondrial energy failure and the inability of the TCA to supply reduced 
cofactors might affect the mitochondrial respiratory chain.  
Our data support the link between heme biosynthesis, energetic metabolism 
and nutritional context. However, more experiments are required. 
These data support the evidence that porphyrias are genetic complex 
diseases, in which alterations in other metabolisms contribute to the onset of 
the disease. The hiPSC derived HLCs to model porphyrias would be an 
important tool to allow further experiments as RNA-seq analysis applied in 
an hepatic contest, in which the disease take place. The capacity of 
generation of different cells type is also important to study the effect of the 
porphyrins production in different tissues in a genetic patient-specific context. 
Further, exome sequencing analysis on a large cohort of porphyria patients 
combined with tissue specific metabolic analysis will be potent devices to 
characterize the disease in an overall way. 
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CONCLUSIONS, SHORTCOMINGS OF THE CURRENT STUDY AND 
FUTURE DIRECTIVES 
In this project, we characterized the functional role of three new variants in 
the regulatory regions of PPOX gene suggesting a transcriptional 
involvement for the c.1-883 G>C variant and a putative translational effect 
for the c.1-413G>T. The c.1-176 G>A produce an alternative splicing variant 
for the PPOX gene that does not affect the mRNA level of PPOX. 
 These data evidence the inclusion of the regulatory regions in the diagnostic 
process of porphyrias. Further experiments as electrophoresis mobility shift 
assay (EMSA) or cell manipulations generated by CRISPR/Cas9 could clarify 
the direct action of the variants in the transcription and protein level of PPOX. 
The generation of iPSC-derived hepatocytes cells like, are a valid tool to 
investigate the transcriptional and metabolic alterations involved in acute 
intermittent porphyria at hepatic level in a patient specific background 
contest. 
However, improvement in hepatic differentiation protocol and further 
functional and biochemical analysis are required to better understand the 
metabolic network linked with heme biosynthetic pathway. 
The quantification of the glucose consumption and pyruvate and lactate 
production could better support the crosstalk between heme synthesis, 
respiratory chain and TCA cycle (experiments ongoing).  
Moreover, the measurement of intracellular and released porphyrins 
(experiments ongoing) could show a link between induction of the pathway 
and overproduction of porphyrins, responsible of the metabolic changes and 
probably linked with the symptoms of the disease. To highlight a common 
response to the different endogenous and exogenous stimuli however, the 
recruitment of more patients and controls is required. 
Another important experiment for the interpretation of the data is the 
correction of the mutation in the AIP lines to validate the metabolic changes 
suggested by the current studies. It is well known that the single mutation 
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does not correlate with the phenotype as evidence of the low penetrance of 
porphyrias. For that reason, a combined use of the piggy bag transposon 
vector and CRISPR/Cas9 system to replace the wild type base is proposed 
as strategy for the correction of the mutations. Further studies on correct 
lines will have the potential to explain the origin of the metabolic alterations 
as either connected to the mutation or derived from the genetic background 
of the patient lines.  
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